DARE — Dare Bioscience, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1401914 ·
Last close
$0.78
Market Cap
$15.26M
52W High
$3.78
52W Low
$0.69
ADV30
685,980
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 187,546 | -132,343 | -2,967,980 | -2,982,773 | 22,370,109 | 12,617,594 | 22,930,209 |
| Mar 2026 | 152,455 | -89,870 | -2,998,898 | -2,999,889 | 27,828,414 | 18,519,784 | 27,093,963 |
| Dec 2025 | 1,023,676 | 727,877 | -1,471,268 | -1,441,718 | 32,474,563 | 24,711,356 | 29,631,929 |
| Sep 2025 | 2,262 | 2,262 | -3,672,148 | -3,562,766 | 30,748,574 | 23,075,261 | 27,890,671 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-9,935,971
Investing CF
$-227,947
Financing CF
$18,315,097
CapEx
$-1,101,523
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.44
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-191,688,793
Inventory
—
Receivables
$687,756
ST Investments
—
EBIT TTM
$-11,970,114
Pretax Income TTM
$-12,020,856
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,365,939
EBITDA
$-8,978,829
Free Cash Flow
$-6,908,168
Enterprise Value
$4,941,179
Total Cash
$12,617,594
Total Debt
$6,763,626
Shares Out
19,669,083
Trailing EPS
$-0.66
Book Value
$-0.04
ROE
—
ROA
-39.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,030,193 | -13,552,334 | -13,399,274 | 32,474,563 | 29,631,929 | 2,842,634 | -9,885,870 |
| Dec 2024 | 9,784 | -23,451,485 | -4,053,599 | 22,101,131 | 28,113,220 | -6,012,089 | 5,473,555 |
| Dec 2023 | 2,807,885 | -30,939,880 | -30,161,391 | 21,282,215 | 26,329,855 | -5,047,640 | -38,856,654 |
| Dec 2022 | 10,000,000 | -31,385,488 | -30,947,738 | 43,826,383 | 32,714,273 | 11,112,110 | -18,088,429 |
TTM Snapshot
Revenues TTM
$1,067,118
NetIncome TTM
$-24,399,747
OpCashFlow TTM
$0
Assets (Latest)
$32,474,563
Forward EPS
$-0.41
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LTRN | Lantern Pharma Inc. | $15.60M | $1.22 | — |
| CMMB | Chemomab Therapeutics Ltd. | $15.83M | $2.16 | — |
| CTXR | Citius Pharmaceuticals, Inc. | $15.90M | $0.58 | — |
| HIND | Vyome Holdings, Inc | $14.32M | $2.04 | — |
| ACTU | ACTUATE THERAPEUTICS, INC. | $16.33M | $0.68 | — |
News headlines (Yahoo Finance, 1h cache)
Dare Bioscience stock rises after receiving HPV treatment patent
2026-09-28 14:32 · Yahoo
Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand
2026-09-11 10:55 · Yahoo
Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth
2026-08-31 12:44 · Yahoo
Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series
2026-08-27 13:01 · Yahoo
Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment
2026-08-25 12:55 · Yahoo
Dare Bioscience Inc (DARE) (Q2 2026) Earnings Call Highlights: Commercial Launch Milestones and ...
2026-08-17 20:34 · Yahoo
DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List
2026-08-18 13:02 · Yahoo
Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
2026-08-14 16:45 · Yahoo
Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances
2026-08-13 20:01 · Yahoo
Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities
2026-07-20 13:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.